Clinical trials: Breast Cancer (Early Breast Cancer)
Triple Negative Breast Cancer, Breast Cancer Stage II
Implantable Microdevice for TNBC - Pilot Study
The goal of this research study is to evaluate the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of a specific drug or combination of drugs as a possible tool to evaluate the…
- Conditions
- Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer
- Trial name
- NCT05774886
- Testing
- Implantable Microdevice (IMD)
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
This single arm, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with a taxane as first line therapy in participants with HER2-positive breast cancer who relapsed after neoadjuvant…
- Trial name
- NCT01301729
- Testing
- Docetaxel, Paclitaxel, Trastuzumab
- Where
- 17 sites in China
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
English Translation (Professional Medical Version) This study is a multicenter, prospective clinical trial designed to investigate the efficacy and safety of neoadjuvant therapy with trastuzumab plus pertuzumab combined with…
- Trial name
- NCT07589972
- Testing
- neoadjuvant therapy
- Volunteers
- 45 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
This is a prospective, multicenter, open label, non-comparative trial in Spain. The primary objective of this study is to determine the complete response, defined as no vomiting and no use of rescue treatment, in women with…
- Trial name
- NCT01298193
- Testing
- Aprepitant
- Where
- 13 sites in Spain
- Volunteers
- 212 people
- Sponsor
- Spanish Breast Cancer Research Group
Neoadjuvant Therapy
Neoadjuvant SNF Precision Therapy Phase III
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial designed to compare the efficacy and safety of neoadjuvant chemotherapy based on SNF classification with or without precision…
- Trial name
- NCT06913777
- Testing
- Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC)
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Fudan University
Breast Cancer
What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol
This study aims to identify key benefits and harms of integrating risk stratification (the BC-Predict intervention) into the NHS Breast Screening Programme.
- Trial name
- NCT04359420
- Testing
- BC-Predict, NHS Breast Screening Programme
- Where
- United Kingdom
- Volunteers
- 32,298 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Triple-negative Breast Cancer
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
Objective to evaluate the efficacy and safety of neoadjuvant therapy with Chidamide combined with chemotherapy for stage II - III triple-negative breast cancer，and to compare the efficacy and safety of chemotherapy with Chidamide…
- Trial name
- NCT04582955
- Testing
- Chidamide in combination with chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer
This is a multicenter, observational validation study designed to evaluate the prognostic performance of the PORTENT algorithm in patients with early-stage breast cancer.
- Trial name
- PORTENT (NCT07372261)
- Testing
- Validation of Prognostic tool
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Triple Negative Breast Neoplasms
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Neoadjuvant treatment is an important part of the treatment strategy for locally advanced TNBC having established a positive and significant correlation of pathologic Complete Response (pCR) with long-term clinical benefit such…
- Trial name
- neoBREASTIM (NCT06067061)
- Testing
- Atezolizumab + RP1
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Curie
Early Breast Cancer
Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer
The aim of this study is to prospectively evaluate, in patients affected by early breast cancer, safety and feasibility of single fraction radiotherapy with Cyberknife R in preoperative setting, and to identify factors predictive…
- Trial name
- ROCK (NCT03520894)
- Testing
- Neoadjuvant radiotherapy
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Breast Cancer
IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer
The purpose of this study is to evaluate an investigational way to provide radiation therapy to treat breast cancer at the time of surgery.
- Trial name
- NCT01988870
- Testing
- Intra-operative Radiation Therapy (IORT)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Shayna Showalter, MD
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Breast Cancer, BRCA 1 Gene Mutation
A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
This study aims to learn whether a handheld robotic device, called the HandX, can help surgeons safely perform a minimally invasive nipple-sparing mastectomy.
- Conditions
- Breast Cancer, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Hereditary Breast Carcinoma
- Trial name
- ATHENA I (NCT07292246)
- Testing
- Endoscopic nipple sparing mastectomy, HandX endoscopic instrument
- Where
- Greece
- Volunteers
- 15 people
- Sponsor
- Vasileios Kalles
Breast Cancer Female
Young Patients With Early Breast Cancer
The prognosis of young patients with breast cancer is relatively poor. Chemotherapy damages ovarian function. Endocrine treatment for up to 10 years delays the childbearing time of patients.
- Trial name
- NCT06027541
- Testing
- operation
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant…
- Trial name
- NCT06106477
- Testing
- Intermittent Fasting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
HER2-positive Breast Cancer, Early-stage Breast Cancer
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and…
- Conditions
- HER2-positive Breast Cancer, Early-stage Breast Cancer, Breast Cancer, Breast Neoplasms
- Trial name
- NCT04109391
- Testing
- TX05 (trastuzumab), Herceptin (trastuzumab)
- Where
- 86 sites in Belarus, Chile and 8 more
- Volunteers
- 338 people
- Sponsor
- Tanvex BioPharma USA, Inc.
Breast Cancer
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
This study evaluates whether there are pre-treatment factors such as patient characteristics, specific breast cancer type, specific treatments, toxicities, or adverse events during treatment that may impact the quality of life…
- Trial name
- NCT05926024
- Testing
- Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Early Breast Cancer
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI) intolerance.
- Trial name
- NCT07541079
- Testing
- Giredestrant
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Genentech, Inc.
Breast Cancer
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
The purpose of this trial is to estimate the recommended dose (RD) of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor…
- Trial name
- NCT05870579
- Testing
- [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib
- Where
- 13 sites in United States, China and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
HER2+ Breast Cancer
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment…
- Trial name
- NCT06537674
- Testing
- Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
- Volunteers
- 100 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.